Balder Patients with early-stage ovarian cancer may achieve long-term survival with standard treatment, and some patients can survive for 30 years or more. The prognosis of early ovarian cancer is closely related to pathological stage, degree of differentiation, treatment plan and individual differences. The main influencing factors include tumor localization without spread, low-grade histological type, standard surgery combined with chemotherapy, close follow-up monitoring and genetic status.
1. The tumor is localized and has not spread
The five-year survival rate of stage IA patients limited to the ovary or pelvis is higher, and the ten-year survival rate is significantly improved after complete tumor removal. At this time, the tumor has not infiltrated adjacent organs and there is no peritoneal implantation or metastasis, and the operation can meet the R0 resection standard. After such patients undergo comprehensive staging surgery, some cases can achieve clinical cure without adjuvant chemotherapy.
2. Low-grade histology type
Low-malignancy subtypes, such as well-differentiated serous carcinoma or grade I endometrioid carcinoma, grow slowly and are sensitive to platinum-based chemotherapy. This type of tumor has small cell atypia, few mitotic figures, low Ki-67 proliferation index, and a significantly lower risk of recurrence than high-grade tumors. Those who are positive for ER/PR hormone receptors in pathological tests may respond well to endocrine therapy.
3. Standardized surgery combined with chemotherapy
Comprehensive staging surgery combined with TC regimen chemotherapy is the standard treatment model. Surgery requires removal of both uterine appendages, omentum and peritoneal multiple biopsy points, and chemotherapy is often performed with paclitaxel combined with carboplatin. Patients with BRCA1/2 mutations may benefit from maintenance therapy with PARP inhibitors, which can significantly extend progression-free survival. Some young patients may consider fertility-sparing surgery.
4. Close follow-up and monitoring
CA125 and pelvic ultrasound should be reviewed every 3 months for the first two years after treatment, and enhanced CT should be reviewed every 6 months for five years. When CA125 doubles or imaging abnormalities are found during monitoring, timely intervention can improve the secondary remission rate. Lifestyle management, including weight control, vitamin D supplementation, and regular exercise, may reduce the risk of recurrence.
5. Genetic status
Although BRCA1/2 germline mutation carriers are at high risk, they are sensitive to platinum and PARP inhibitor treatment. Such patients are usually younger when diagnosed and have good basic physical conditions. After receiving genetic counseling and risk management, some can achieve ultra-long-term survival. Patients with mismatch repair gene deletions may benefit from immune checkpoint inhibitor therapy.
Patients with early-stage ovarian cancer should maintain regular follow-up. Those with no signs of recurrence within five years after treatment have a significantly higher probability of long-term survival. Pay attention to a balanced diet every day, supplement appropriate amounts of high-quality protein and antioxidant foods, and avoid estrogen-containing health products. Carry out moderate aerobic exercise according to physical fitness, and conduct bone density monitoring regularly. Psychologically, positive treatment beliefs need to be established, and family members should cooperate in creating a supportive environment and seek professional psychological counseling services when necessary.
